Alpha 0.1.0

Biotech411

Biotechnology. Right now.

All programs

Oncology

Rybrevant Faspro · head and neck cancer

Accelerated approval · As of

OrigAMI-4 examined amivantamab in head and neck cancer. FDA based the new indication on a group of 102 previously treated patients.

Milestone history

  1. OrigAMI-4 (NCT06385080) began.

    ClinicalTrials.gov
  2. FDA granted accelerated approval for eligible adults with recurrent or metastatic disease after platinum and PD-(L)1 therapy.

    FDA